FDA approves Watson's new formulation of Trelstar for prostate cancer
This article was originally published in Scrip
Executive Summary
The US FDA has approved Watson Pharmaceutical's six-month formulation of Trelstar, Trelstar 22.5 mg (triptorelin pamoate for injectable suspension), for the treatment of advanced prostate cancer. Launch is expected in May.